The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas

Yoshihiro Komohara, Tomoko Morita, Dorcas A. Annan, Hasita Horlad, Koji Ohnishi, Sohsuke Yamada, Toshiyuki Nakayama, Shohei Kitada, Shinya Suzu, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Koichi Akashi, Motohiro Takeya, Masahisa Jinushi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Clear cell renal cell carcinoma (ccRCC) is one of most common cancers in urogenital organs. Although recent experimental and clinical studies have shown the immunogenic properties of ccRCC as illustrated by the clinical sensitivities to various immunotherapies, the detailed immunoregulatory machineries governing the tumorigenicity of human ccRCC remain largely obscure. In this study, we demonstrated the clinical significance and functional relevance of T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) expressed on tumor cells and myeloid cells in patients with ccRCC. TIM-3 expression was detected on cancer cells and CD204+ tumor-associated macrophages (TAM), and higher expression level of TIM-3 was positively correlated with shorter progression-free survival (PFS) in patients with ccRCC. We found that TIM-3 expression was detected on a large number of tumors, and there was significant correlation between an increased number of TAMs and high expression level of TIM-3 in patients with ccRCC. Furthermore, TIM-3 rendered RCC cells with the ability to induce resistance to sunitinib and mTOR inhibitors, the standard regimen for patients with ccRCC, as well as stem cell activities. TIM-3 expression was induced on CD14+ monocytes upon long-term stimulation with RCC cells, and TIM-3-expressing myeloid cells play a critical role in augmenting tumorigenic activities of TIM-3-negative RCC cells. More importantly, treatment with anti-TIM-3 mAb suppressed its tumorigenic effects in in vitro and in vivo settings. These findings indicate the coordinated action of TIM-3 in cancer cells and in myeloid cells regulates the tumorigenicity of human RCC.

Original languageEnglish
Pages (from-to)999-1007
Number of pages9
JournalCancer Immunology Research
Volume3
Issue number9
DOIs
Publication statusPublished - Sep 2015

Fingerprint

Myeloid Cells
Renal Cell Carcinoma
Neoplasms
Urogenital Neoplasms
Mucins
Immunotherapy
Disease-Free Survival
Monocytes
Stem Cells
Macrophages
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology
  • Cancer Research

Cite this

The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. / Komohara, Yoshihiro; Morita, Tomoko; Annan, Dorcas A.; Horlad, Hasita; Ohnishi, Koji; Yamada, Sohsuke; Nakayama, Toshiyuki; Kitada, Shohei; Suzu, Shinya; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Akashi, Koichi; Takeya, Motohiro; Jinushi, Masahisa.

In: Cancer Immunology Research, Vol. 3, No. 9, 09.2015, p. 999-1007.

Research output: Contribution to journalArticle

Komohara, Y, Morita, T, Annan, DA, Horlad, H, Ohnishi, K, Yamada, S, Nakayama, T, Kitada, S, Suzu, S, Kinoshita, I, Dosaka-Akita, H, Akashi, K, Takeya, M & Jinushi, M 2015, 'The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas', Cancer Immunology Research, vol. 3, no. 9, pp. 999-1007. https://doi.org/10.1158/2326-6066.CIR-14-0156
Komohara, Yoshihiro ; Morita, Tomoko ; Annan, Dorcas A. ; Horlad, Hasita ; Ohnishi, Koji ; Yamada, Sohsuke ; Nakayama, Toshiyuki ; Kitada, Shohei ; Suzu, Shinya ; Kinoshita, Ichiro ; Dosaka-Akita, Hirotoshi ; Akashi, Koichi ; Takeya, Motohiro ; Jinushi, Masahisa. / The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. In: Cancer Immunology Research. 2015 ; Vol. 3, No. 9. pp. 999-1007.
@article{4444e01cceac4cb1aec6f3313da5aa8c,
title = "The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas",
abstract = "Clear cell renal cell carcinoma (ccRCC) is one of most common cancers in urogenital organs. Although recent experimental and clinical studies have shown the immunogenic properties of ccRCC as illustrated by the clinical sensitivities to various immunotherapies, the detailed immunoregulatory machineries governing the tumorigenicity of human ccRCC remain largely obscure. In this study, we demonstrated the clinical significance and functional relevance of T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) expressed on tumor cells and myeloid cells in patients with ccRCC. TIM-3 expression was detected on cancer cells and CD204+ tumor-associated macrophages (TAM), and higher expression level of TIM-3 was positively correlated with shorter progression-free survival (PFS) in patients with ccRCC. We found that TIM-3 expression was detected on a large number of tumors, and there was significant correlation between an increased number of TAMs and high expression level of TIM-3 in patients with ccRCC. Furthermore, TIM-3 rendered RCC cells with the ability to induce resistance to sunitinib and mTOR inhibitors, the standard regimen for patients with ccRCC, as well as stem cell activities. TIM-3 expression was induced on CD14+ monocytes upon long-term stimulation with RCC cells, and TIM-3-expressing myeloid cells play a critical role in augmenting tumorigenic activities of TIM-3-negative RCC cells. More importantly, treatment with anti-TIM-3 mAb suppressed its tumorigenic effects in in vitro and in vivo settings. These findings indicate the coordinated action of TIM-3 in cancer cells and in myeloid cells regulates the tumorigenicity of human RCC.",
author = "Yoshihiro Komohara and Tomoko Morita and Annan, {Dorcas A.} and Hasita Horlad and Koji Ohnishi and Sohsuke Yamada and Toshiyuki Nakayama and Shohei Kitada and Shinya Suzu and Ichiro Kinoshita and Hirotoshi Dosaka-Akita and Koichi Akashi and Motohiro Takeya and Masahisa Jinushi",
year = "2015",
month = "9",
doi = "10.1158/2326-6066.CIR-14-0156",
language = "English",
volume = "3",
pages = "999--1007",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas

AU - Komohara, Yoshihiro

AU - Morita, Tomoko

AU - Annan, Dorcas A.

AU - Horlad, Hasita

AU - Ohnishi, Koji

AU - Yamada, Sohsuke

AU - Nakayama, Toshiyuki

AU - Kitada, Shohei

AU - Suzu, Shinya

AU - Kinoshita, Ichiro

AU - Dosaka-Akita, Hirotoshi

AU - Akashi, Koichi

AU - Takeya, Motohiro

AU - Jinushi, Masahisa

PY - 2015/9

Y1 - 2015/9

N2 - Clear cell renal cell carcinoma (ccRCC) is one of most common cancers in urogenital organs. Although recent experimental and clinical studies have shown the immunogenic properties of ccRCC as illustrated by the clinical sensitivities to various immunotherapies, the detailed immunoregulatory machineries governing the tumorigenicity of human ccRCC remain largely obscure. In this study, we demonstrated the clinical significance and functional relevance of T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) expressed on tumor cells and myeloid cells in patients with ccRCC. TIM-3 expression was detected on cancer cells and CD204+ tumor-associated macrophages (TAM), and higher expression level of TIM-3 was positively correlated with shorter progression-free survival (PFS) in patients with ccRCC. We found that TIM-3 expression was detected on a large number of tumors, and there was significant correlation between an increased number of TAMs and high expression level of TIM-3 in patients with ccRCC. Furthermore, TIM-3 rendered RCC cells with the ability to induce resistance to sunitinib and mTOR inhibitors, the standard regimen for patients with ccRCC, as well as stem cell activities. TIM-3 expression was induced on CD14+ monocytes upon long-term stimulation with RCC cells, and TIM-3-expressing myeloid cells play a critical role in augmenting tumorigenic activities of TIM-3-negative RCC cells. More importantly, treatment with anti-TIM-3 mAb suppressed its tumorigenic effects in in vitro and in vivo settings. These findings indicate the coordinated action of TIM-3 in cancer cells and in myeloid cells regulates the tumorigenicity of human RCC.

AB - Clear cell renal cell carcinoma (ccRCC) is one of most common cancers in urogenital organs. Although recent experimental and clinical studies have shown the immunogenic properties of ccRCC as illustrated by the clinical sensitivities to various immunotherapies, the detailed immunoregulatory machineries governing the tumorigenicity of human ccRCC remain largely obscure. In this study, we demonstrated the clinical significance and functional relevance of T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) expressed on tumor cells and myeloid cells in patients with ccRCC. TIM-3 expression was detected on cancer cells and CD204+ tumor-associated macrophages (TAM), and higher expression level of TIM-3 was positively correlated with shorter progression-free survival (PFS) in patients with ccRCC. We found that TIM-3 expression was detected on a large number of tumors, and there was significant correlation between an increased number of TAMs and high expression level of TIM-3 in patients with ccRCC. Furthermore, TIM-3 rendered RCC cells with the ability to induce resistance to sunitinib and mTOR inhibitors, the standard regimen for patients with ccRCC, as well as stem cell activities. TIM-3 expression was induced on CD14+ monocytes upon long-term stimulation with RCC cells, and TIM-3-expressing myeloid cells play a critical role in augmenting tumorigenic activities of TIM-3-negative RCC cells. More importantly, treatment with anti-TIM-3 mAb suppressed its tumorigenic effects in in vitro and in vivo settings. These findings indicate the coordinated action of TIM-3 in cancer cells and in myeloid cells regulates the tumorigenicity of human RCC.

UR - http://www.scopus.com/inward/record.url?scp=84961994266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961994266&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-14-0156

DO - 10.1158/2326-6066.CIR-14-0156

M3 - Article

C2 - 25783986

AN - SCOPUS:84961994266

VL - 3

SP - 999

EP - 1007

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 9

ER -